Predict your next investment

Corporation
cetero.com

See what CB Insights has to offer

About Cetero Research

Cetero Research isa CRO in clinical pharmacology, bioanalytical, and specialty Phase II-IV services. With more than 25 years of experience fromCetero Research's founding companies, we have conducted more clinical pharmacology studies than any other CRO.Cetero Research's proven track record allows us to provide flexible and reliable drug development services.Cetero Research's time-tested systems produce quality dataCetero Research's clients can trust.Cetero Research's clinical research expertise spans Phase I to IV. Cetero's bioanalytical services support clinical, pre-clinical drug and biomarker analysis for small and large molecules.

Cetero Research Headquarter Location

400 Fountain Lakes Boulevard

Saint Charles, Missouri, 63301-4349,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Cetero Research News

FDA has history of hiding scientific misconduct

Apr 19, 2013

This week, we reported that the Food and Drug Administration left medicines on the market for years after discovering they were approved based on fraudulent studies by Cetero Research, which did testing for drug companies worldwide. Turns out that wasn't an anomaly: The agency's slow, secretive response in the Cetero case mirrors how it handled an earlier instance of scientific misconduct at another contract research organization, MDS Pharma Services. The FDA found that data prod

Cetero Research Acquisitions

1 Acquisition

Cetero Research acquired 1 company. Their latest acquisition was Cetero Research on October 20, 2006.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

10/20/2006

Private Equity

$83M

Acquired

Date

10/20/2006

Investment Stage

Private Equity

Companies

Valuation

Total Funding

$83M

Note

Acquired

Sources

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.